DE60033814T2 - Monoklonaler Antikörper der Faktor VIII selbst in molarem Überschuß nur teilweise inaktiviert und eine Methode zur Herstellung solch eines Antikörpers - Google Patents

Monoklonaler Antikörper der Faktor VIII selbst in molarem Überschuß nur teilweise inaktiviert und eine Methode zur Herstellung solch eines Antikörpers Download PDF

Info

Publication number
DE60033814T2
DE60033814T2 DE60033814T DE60033814T DE60033814T2 DE 60033814 T2 DE60033814 T2 DE 60033814T2 DE 60033814 T DE60033814 T DE 60033814T DE 60033814 T DE60033814 T DE 60033814T DE 60033814 T2 DE60033814 T2 DE 60033814T2
Authority
DE
Germany
Prior art keywords
factor viii
monoclonal antibody
factor
human
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60033814T
Other languages
German (de)
English (en)
Other versions
DE60033814D1 (de
Inventor
Marc G. Jacquemin
Jean-Marie R. Saint-Remy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Desire Collen Research Foundation vzw
Original Assignee
Desire Collen Research Foundation vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9916450.1A external-priority patent/GB9916450D0/en
Application filed by Desire Collen Research Foundation vzw filed Critical Desire Collen Research Foundation vzw
Application granted granted Critical
Publication of DE60033814D1 publication Critical patent/DE60033814D1/de
Publication of DE60033814T2 publication Critical patent/DE60033814T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60033814T 1999-07-14 2000-07-13 Monoklonaler Antikörper der Faktor VIII selbst in molarem Überschuß nur teilweise inaktiviert und eine Methode zur Herstellung solch eines Antikörpers Expired - Lifetime DE60033814T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14389199P 1999-07-14 1999-07-14
US143891P 1999-07-14
GBGB9916450.1A GB9916450D0 (en) 1999-07-14 1999-07-14 Ligands for use in therapeutic compounds for the treatment of hemostasis disorders
GB9916450 1999-07-14
PCT/EP2000/006677 WO2001004269A1 (en) 1999-07-14 2000-07-13 Ligands for use in therapeutic compositions for the treatment of hemostasis disorders

Publications (2)

Publication Number Publication Date
DE60033814D1 DE60033814D1 (de) 2007-04-19
DE60033814T2 true DE60033814T2 (de) 2007-11-08

Family

ID=26315767

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60033814T Expired - Lifetime DE60033814T2 (de) 1999-07-14 2000-07-13 Monoklonaler Antikörper der Faktor VIII selbst in molarem Überschuß nur teilweise inaktiviert und eine Methode zur Herstellung solch eines Antikörpers

Country Status (11)

Country Link
EP (1) EP1194528B1 (cg-RX-API-DMAC7.html)
JP (2) JP4297207B2 (cg-RX-API-DMAC7.html)
AT (1) ATE356201T1 (cg-RX-API-DMAC7.html)
AU (1) AU781638B2 (cg-RX-API-DMAC7.html)
CA (1) CA2381125C (cg-RX-API-DMAC7.html)
CY (1) CY1107638T1 (cg-RX-API-DMAC7.html)
DE (1) DE60033814T2 (cg-RX-API-DMAC7.html)
DK (1) DK1194528T3 (cg-RX-API-DMAC7.html)
ES (1) ES2283308T3 (cg-RX-API-DMAC7.html)
PT (1) PT1194528E (cg-RX-API-DMAC7.html)
WO (1) WO2001004269A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829085B2 (en) 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
DK1222929T3 (da) 2001-01-11 2010-09-06 Life Sciences Res Partners Vzw Fremgangsmåde og farmaceutisk sammensætning til forebyggelse og/eller behandling af systematisk betændelsesreaktionssyndrom
AU2002313194B9 (en) * 2001-06-12 2008-06-05 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human-type anti-blood coagulation factor VIII antibody
EP1388544A1 (en) 2002-07-31 2004-02-11 D. Collen Research Foundation vzw Anti-idiotypic antibodies against factor VIII inhibitor and uses thereof
JP4422430B2 (ja) 2003-05-14 2010-02-24 帝國製薬株式会社 エストロゲン及び／又はプロゲストゲン含有外用貼付剤
CA2535489C (en) 2003-08-14 2014-09-30 D. Collen Research Foundation Vzw Antibodies against factor viii with modified glycosylation in the variable region
US7566701B2 (en) 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
AU2005282380A1 (en) 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
ATE509957T1 (de) * 2005-07-29 2011-06-15 Life Sciences Res Partners Vzw An die a2-domäne bindende, humane inhibitorische anti-faktor-viii-antikörper
FR2892724B1 (fr) 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
FR2897868B1 (fr) * 2006-02-24 2012-08-31 Lab Francais Du Fractionnement Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii.
NZ597452A (en) 2009-07-10 2013-10-25 Thrombogenics Nv Variants of plasminogen and plasmin
WO2011023805A1 (en) 2009-08-28 2011-03-03 Thrombogenics N.V. Use of plasmin for the treatment of filtration failure after trabeculectomy
CA2823491A1 (en) 2011-01-05 2012-07-12 Thrombogenics Nv Plasminogen and plasmin variants
CA2844644A1 (en) 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
EP2785739B1 (en) 2011-12-01 2017-03-15 ThromboGenics N.V. Improving trabeculectomy outcome
KR101395736B1 (ko) * 2012-07-10 2014-05-16 아주대학교산학협력단 인간 혈액응고인자 ⅷ 도메인 특이적 항체 및 이의 제조방법
EP3426685A1 (en) 2016-03-10 2019-01-16 Oxurion NV Posterior ocular fibrosis inhibition by antagonizing placental growth factor
KR20200005635A (ko) * 2017-05-11 2020-01-15 브이아이비 브이지더블유 가변 면역글로불린 도메인의 글리코실화

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose

Also Published As

Publication number Publication date
ATE356201T1 (de) 2007-03-15
DK1194528T3 (da) 2007-07-09
CA2381125C (en) 2013-04-23
EP1194528A1 (en) 2002-04-10
JP4297207B2 (ja) 2009-07-15
CY1107638T1 (el) 2013-04-18
AU6273000A (en) 2001-01-30
JP2003504045A (ja) 2003-02-04
JP4297225B2 (ja) 2009-07-15
CA2381125A1 (en) 2001-01-18
JP2008295455A (ja) 2008-12-11
AU781638B2 (en) 2005-06-02
EP1194528B1 (en) 2007-03-07
PT1194528E (pt) 2007-05-31
WO2001004269A1 (en) 2001-01-18
DE60033814D1 (de) 2007-04-19
ES2283308T3 (es) 2007-11-01

Similar Documents

Publication Publication Date Title
DE69736197T2 (de) Antikoagulierende humanisierte Antikörper gegen Faktor IX, zur Verwendung in der Behandlung von Thrombose
JP4297225B2 (ja) 止血障害処置のための治療組成物に使用するためのリガンド
DE60035356T2 (de) Faktor ix/faktor ixa aktivierende antikörper
DE69132352T2 (de) Protein-antagonisten der blut-koagulation und ihre verwendung
EP2297207B1 (en) Use of anti-factor xi antibodies for prevention or treatment of thrombus formation
DE69006851T2 (de) Blutgerinnungshemmende zusammensetzungen aus faktor xa.
CN109153726A (zh) 抗因子xi的活性位点的单克隆抗体及其用途
DE60032029T2 (de) Antithrombose agenzien
DE69011531T2 (de) Von faktor vii abgeleitete peptide mit antihämostatischer wirkung.
DE69232669T2 (de) Mit gp11b/iiia reaktive humane antikörper
DE69621591T2 (de) Medikament welches Protein C aktivierendes Peptid enthält
US20030175268A1 (en) Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome
US20020136725A1 (en) Antithrombotic agents
DE68919504T2 (de) Beschleunigung der Lyse von Gerinnsel.
US7067313B1 (en) Ligands for use in therapeutic compositions for the treatment of hemostasis disorders
EP1222929B1 (en) Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome
DE60033234T2 (de) Zelllinien, liganden und antikörperfragmente zur verwendung in pharmazeutischen zusammensetzungen zur vorbeugung und behandlung von krankhaften veränderungen der homöostase
DE19820663A1 (de) Rekombinante Antikörper
HK1029513B (en) Anticoagulant humanised antibodies against factor ix, for use in the treatment of thrombosis
HK1109339A (en) Antithrombotic agents
HK1107932A (en) Anticoagulant agents useful in treatment of thrombosis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition